Celebrex

Basic Celebrex Information

• INN (International Nonproprietary Name): Celecoxib
• Brand Names Available In Australia: not specified
• ATC Code: M01AH01
• Forms & Dosages: Capsule 100 mg and 200 mg (blister packs 10/30/60); Oral solution 25 mg/mL (Elyxyb®, US only)
• Manufacturers In Australia: not specified
• Registration Status In Australia: not specified
• OTC / Rx Classification: Prescription Only (RX) worldwide

Neueste Forschungsergebnisse (Austrian + EU Data; 2022–2025)

Worried about recent safety updates for COX‑2 inhibitors like celecoxib?

Regulatory and post‑marketing attention in Europe continues to focus on the balance between gastrointestinal benefits and cardiovascular risks for selective COX‑2 inhibitors.

EMA approval status for celecoxib remains as a prescription medicine and product information emphasises careful patient selection and lowest effective dosing.

Austrian pharmacoepidemiology efforts use prescription datasets such as Sozialversicherung and E‑Medikation for real‑world safety monitoring, although specific 2022–2025 study details are not specified in the available product information.

Clinical practice and regulators compare celecoxib’s GI tolerability against potential cardiovascular signals when choosing long‑term therapy.

Key datapoints: INN = celecoxib; ATC = M01AH01; EMA approval = prescription only; common capsule strengths = 100 mg and 200 mg; oral solution (Elyxyb®) available in the US.

Clinical Effectiveness In Austria

Want to know how well celecoxib works for osteoarthritis and other rheumatic conditions in everyday Austrian practice?

Austrian prescribing mirrors EMA indications, with celecoxib mainly used for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and specialist paediatric use for juvenile idiopathic arthritis (≥2 years).

Real‑world prescribing data from Sozialversicherung and E‑Medikation show celecoxib is often chosen for patients where gastrointestinal tolerability is a priority or where conventional NSAIDs have failed.

Rheumatology clinics report symptomatic pain reduction and improved mobility at recommended doses such as 200 mg once daily or 100 mg twice daily for osteoarthritis.

• Outcome Measures: Pain VAS (visual analogue scale), Function Scores (e.g. WOMAC), Patient Global Assessment, Mobility tests.
• Monitoring: baseline renal, hepatic and cardiovascular assessments before maintenance therapy; pharmacists flag interactions through E‑Medikation alerts.

Data highlight — Common Austrian Dosing Patterns: Osteoarthritis commonly treated with 200 mg once daily or 100 mg twice daily; rheumatoid arthritis frequently dosed 100–200 mg twice daily.

Indications And Extended Uses

Which conditions is celecoxib approved for, and where might it be used outside the label?

1. Osteoarthritis → Typical Dose: 200 mg once daily or 100 mg twice daily → Reimbursement Note: dependent on Sozialversicherung criteria and guideline indications.
2. Rheumatoid Arthritis → Typical Dose: 100–200 mg twice daily → Reimbursement Note: specialist prescription often required for chronic therapy.
3. Ankylosing Spondylitis → Typical Dose: 200 mg once daily or 100 mg twice daily → Reimbursement Note: specialist management common.
4. Acute Pain / Menstrual Cramps → Typical Dose: initial 400 mg then 200 mg as needed on day 1, then 200 mg twice daily → Reimbursement Note: generally not chronic and reimbursement varies.
5. Juvenile Idiopathic Arthritis (Children ≥2 Years) → Typical Dose: weight‑based dosing (often ~50–100 mg twice daily) → Reimbursement Note: specialist paediatric approval required.
6. Familial Adenomatous Polyposis (FAP) → Typical Dose: 400 mg twice daily → Reimbursement Note: specialist oncology/gastroenterology prescribing required.

Off‑label uses in Austria sometimes include short‑term postoperative pain or where gastrointestinal risk excludes nonselective NSAIDs.

Note that Elyxyb® oral solution (25 mg/mL) is approved in some markets such as the US for acute migraine but is not a standard authorised formulation for that indication across the EU.

Prescription‑only status applies across Austria, and paediatric uses are managed by specialists.

Composition And Brand Overview

What exactly is in these medicines and which brands or generics are common?

Active Substance: celecoxib (INN).

Global manufacturer: Pfizer (Celebrex®) and many generic suppliers such as Teva, Mylan, Sandoz, Hikma and Cipla supply celecoxib in various markets.

ATC Code: M01AH01 (selective COX‑2 inhibitor subgroup).

Storage: store below 25°C, keep dry and in the original packaging.

Contraindications And Special Precautions

Who should not take celecoxib, and what should pharmacists watch for?

Absolute Contraindications: known allergy to celecoxib, sulfonamides, NSAIDs or excipients; history of asthma, urticaria or allergic reaction after aspirin/NSAID; active gastrointestinal bleeding or peptic ulcer disease; pregnancy especially in the third trimester.

Relative Contraindications (use with caution and monitoring): established cardiovascular disease or multiple CV risk factors; oedematous states or heart failure; hepatic or renal impairment; controlled asthma or prior GI ulcers.

• Pharmacy Action: document allergy and contraindications in E‑Medikation and refuse dispensing if absolute contraindication is present.
• Patient Advice: avoid driving or operating heavy machinery if dizziness or somnolence occurs; report chest pain, severe abdominal pain or signs of GI bleeding immediately.

Dosage Guidelines (Standard & Adjustments)

How should dosing be tailored for common indications and special populations?

Adjustments And Monitoring:

• Start at the lowest effective dose in elderly patients and monitor renal function and cardiovascular status.
• Reduce initial dose by 50% in moderate hepatic impairment (Child‑Pugh B); avoid in severe hepatic impairment.
• Use caution in renal impairment and generally avoid in severe renal dysfunction.
• For chronic therapy, schedule regular reviews including renal, hepatic and cardiovascular checks.

Overview Of Interactions

What drugs should trigger a pharmacist‑to‑prescriber conversation before dispensing celecoxib?

Celecoxib interacts with several drug classes that are commonly prescribed or used over the counter.

• Anticoagulants / Antiplatelets — increased bleeding risk; monitor INR and bleeding signs when combined with warfarin or antiplatelet agents.
• SSRIs — additive bleeding risk, especially GI bleeding; counsel patients accordingly.
• ACE Inhibitors / ARBs / Diuretics — reduced antihypertensive efficacy and potential renal impairment when combined.
• Methotrexate / Lithium — celecoxib can reduce clearance of these drugs and raise toxicity risk; monitor levels and clinical signs.
• Other NSAIDs / Aspirin — additive gastrointestinal and cardiovascular risks; avoid concomitant NSAID use unless directed by a specialist.

Alcohol increases gastrointestinal risk and patients should be advised to minimise alcohol intake while taking celecoxib.

Pharmacies in Austria use E‑Medikation to flag clinically important interactions at dispensing and follow the Österreichische Apothekerkammer workflows for counselling.

Cultural Considerations And Patient Behaviour In Austria

How do local habits and systems affect access, adherence and choice of celecoxib?

The prescription requirement and the national e‑card E‑Medikation system shape prescribing, interaction checks and reimbursement pathways in Austria.

Rural communities often rely on independent Apotheken and may experience different stock or access compared with urban centres that have nationwide chains such as BENU.

Cross‑border shopping into Germany, the Czech Republic or Hungary occurs in border regions driven by price differences or local availability.

• Adherence Drivers: perceived GI tolerability, once‑daily dosing convenience and cost with generics influence patient choices.
• Pharmacy Role: pharmacists counsel on lowest effective dose, monitor interactions via E‑Medikation and advise about monitoring.

Cultural Insight: cross‑border purchases can interrupt prescription continuity, so patients should bring full prescription details to avoid gaps in therapy.

Availability And Price Overview (Austria)

Where and how can patients get celecoxib in Austria, and what affects cost?

Celecoxib (Celebrex® and multiple generics) is available in Austrian pharmacies by prescription only, and online pharmacy dispensing requires a valid e‑prescription.

Major distribution channels include independent Apotheken and nationwide chains such as BENU, with some retail outlets offering pharmacy counters for limited services.

Generics have reduced patient co‑payments in recent years, and Sozialversicherung reimbursement depends on indication and guideline criteria; specialist prescriptions are often required for chronic indications.

Note: in our online pharmacy, celebrex is available without a prescription, with discreet delivery to Australia in 5‑14 days.

Comparable Medicines And Preferences In Austria

How does celecoxib stack up against other options commonly used by Austrian prescribers?

Patient preference often hinges on dosing convenience (once daily versus multiple doses) and the perceived side‑effect profile when choosing brand versus generic celecoxib.

Frequently Asked Questions

Can I take Celebrex with food?

Yes, celecoxib may be taken with or without food, and taking it with food can reduce stomach upset.

What should I do if I miss a dose?

Take the missed dose as soon as you remember unless it is close to the next scheduled dose, and do not double up.

Can I drink alcohol while on celecoxib?

Alcohol increases the risk of gastrointestinal side effects, so patients should minimise intake and seek advice if they drink heavily.

Is celecoxib safe in pregnancy?

Use should be avoided in pregnancy, particularly in the third trimester, and patients planning pregnancy should discuss alternatives with their prescriber.

Pharmacists should document counselling in E‑Medikation where possible and refer to the product information for storage and missed‑dose instructions.

Guidelines For Correct Use — Patient Counselling According To Austrian Standard

What should pharmacists tell patients at dispensing to ensure safe and effective use?

• Confirm the indication and that a valid prescription (Rezeptpflicht) is present.
• Review E‑Medikation for interactions and allergies, especially sulfonamide or NSAID hypersensitivity.
• Explain dosing clearly: for OA, 200 mg once daily or 100 mg twice daily as an example.
• Describe common adverse effects: dyspepsia, headache, dizziness, hypertension and peripheral oedema.
• Highlight red flags: gastrointestinal bleeding (black stools, severe abdominal pain), chest pain, sudden severe shortness of breath or rash.
• Advise storage: keep below 25°C in the original container and do not use after expiry.
• Recommend follow‑up checks for long‑term therapy including renal, hepatic and cardiovascular monitoring.
• Document counselling in the e‑prescription system and provide a printed or digital handout with the dose and when to seek help.

Delivery Across Australia